Brokers Offer Predictions for Prime Medicine FY2026 Earnings

Prime Medicine logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate to a loss of $0.99 per share from $1.11, while maintaining a Buy rating and an $8 price target.
  • Prime Medicine reported a quarterly loss of $0.22 per share, beating analysts’ estimate of a $0.23 loss; revenue was $4.21 million.
  • Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $7.86, though one analyst rates the stock Sell.
  • Five stocks we like better than Prime Medicine.

Prime Medicine, Inc. (NASDAQ:PRME - Free Report) - Investment analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Prime Medicine in a research note issued to investors on Monday, November 16th. HC Wainwright analyst A. He now expects that the company will earn ($0.99) per share for the year, up from their prior estimate of ($1.11). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Prime Medicine's Q4 2026 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.80) EPS.

Prime Medicine (NASDAQ:PRME - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $4.21 million for the quarter. Prime Medicine had a negative return on equity of 222.88% and a negative net margin of 2,497.56%.

A number of other analysts have also commented on PRME. Weiss Ratings reissued a "sell (e+)" rating on shares of Prime Medicine in a research note on Monday, August 31st. Jefferies Financial Group restated a "market outperform" rating on shares of Prime Medicine in a report on Monday, September 28th. Chardan Capital reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Prime Medicine in a research note on Friday, September 25th. Citigroup reiterated a "market outperform" rating on shares of Prime Medicine in a report on Friday, September 25th. Finally, Wall Street Zen upgraded shares of Prime Medicine from a "sell" rating to a "hold" rating in a report on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Prime Medicine currently has an average rating of "Moderate Buy" and an average price target of $7.86.

Check Out Our Latest Stock Analysis on PRME

Prime Medicine Stock Down 8.4%

Shares of PRME opened at $3.84 on Wednesday. Prime Medicine has a 12-month low of $2.67 and a 12-month high of $5.91. The business has a 50-day simple moving average of $3.71 and a two-hundred day simple moving average of $3.51.

Institutional Trading of Prime Medicine

Institutional investors have recently modified their holdings of the business. Alphabet Inc. acquired a new position in shares of Prime Medicine in the second quarter worth approximately $61,116,000. BlackRock Inc. bought a new stake in Prime Medicine in the second quarter valued at approximately $35,432,000. Sumitomo Mitsui Trust Group Inc. increased its position in Prime Medicine by 20.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,911,596 shares of the company's stock valued at $8,895,000 after purchasing an additional 498,612 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Prime Medicine during the 2nd quarter valued at approximately $7,371,000. Finally, Redmile Group LLC acquired a new stake in Prime Medicine during the 1st quarter valued at approximately $5,536,000. Institutional investors own 70.37% of the company's stock.

Recent Prime Medicine Headlines

These are some of the PRME headlines that stood out recently:

  • Positive Sentiment: HC Wainwright improved its loss forecasts, including Q4 2026 EPS to ($0.26) from ($0.32) and full-year 2026 EPS to ($0.99) from ($1.11). It also modestly raised estimates for 2027–2030, indicating expectations for smaller losses than previously projected. Prime Medicine Stock Rating Reaffirmed as Buy by HC Wainwright
  • Positive Sentiment: The firm reiterated its Buy rating and $8 target, well above the $3.84 reference price in the supplied background, a bullish analyst view that could bolster the stock. HC Wainwright stock recommendations

About Prime Medicine

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Read More

Earnings History and Estimates for Prime Medicine (NASDAQ:PRME)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prime Medicine Right Now?

Before you consider Prime Medicine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.

While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines